Drug
SoC Chemotherapy
SoC Chemotherapy is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
1(33%)
Terminated
1(33%)
Phase Distribution
Ph phase_2
2
67%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Terminated(1)
Detailed Status
Recruiting1
Not yet recruiting1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (66.7%)
Phase 31 (33.3%)
Trials by Status
recruiting133%
not_yet_recruiting133%
terminated133%
Recent Activity
1 active trials
Showing 3 of 3
not_yet_recruitingphase_3
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
NCT07178730
recruitingphase_2
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
NCT05846789
terminatedphase_2
MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC
NCT05114213
Clinical Trials (3)
Showing 3 of 3 trials
NCT07178730Phase 3
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
NCT05846789Phase 2
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
NCT05114213Phase 2
MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3